《新股表現》復宏漢霖(02696.HK)暗盤收報48.5元 低上市價2.2%
據輝立交易平台資料,明日上市的復宏漢霖(02696.HK)今日(24日)暗盤開報50.5元,收報48.5元,較上市價49.6元,低2.2%或1.1元,成交12.8萬股,涉622萬元。不計手續費,每手100股賬面蝕110元。
由復星醫藥(02196.HK)分拆之復宏漢霖每股定價49.6元,為招股價範圍下限(介乎每股49.6元至57.8元),集資淨額約30.96億元。是次香港公開發售錄得超額認購2.89倍,而國際發售部分獲適度超額認購,一手100股,中籤率100%。股份將於明日(25日)上市。中金公司、美銀美林、招銀國際、復星恆利以及花旗擔任聯席保薦人。
公司集資所得款項淨額的40%將用於撥付持續進行的核心產品的臨床試驗、監管備案及註冊;15%將用於撥付持續進行的其他候選生物類似藥的臨床試驗、監管備案及註冊;以及35%將用於撥付持續進行的生物創新藥的臨床試驗、監管備案及註冊以及開發免疫腫瘤聯合療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.